Publications

Please Click on Publication Title to Download.
Publications are sorted by category:
General Interest, 5-FU, Paclitaxel and Docetaxel.

General Interest

Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: Does it make a difference?
Mathijssen RHJ, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. The Oncologist. 2007;12:913-923. doi:10.1634/theoncologist.12-8-913.

Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
de Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH. Clin
Pharmacokinet. 2005;44(2):147-173.

Pharmacokinetic variability of anticancer agents.
Undevia SD, Gomez-Abuin G, Ratain MJ. Nat Rev Cancer. 2005;5(6):447-458.

Timeline: Chemotherapy and the war on cancer.
Chabner BA, Roberts TG Jr.
Nat Rev Cancer. 2005;5(1):65-72.

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Lyman GH, Dale DC, Crawford J.
J Clin Oncol. 2003;21(24):4524-4531.

Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
Rousseau A, Marquet P.
Fundam Clin Pharmacol. 2002;16(4):253-262.

Pharmacogenetics of cancer therapy: getting personal.
Krynetski EY, Evans WE.
Am J Hum Genet. 1998;63(1):11-16.

Therapeutic drug monitoring in cancer management.
Galpin AJ, Evans WE.
Clin Chem. 1993;39(11, Pt 2):2419-2430.

5-Fluorouracil (5-FU)

Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared with Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study.
Capitain, O, Asevoaia, A, et al.
Clin Colorectal Cancer. 2012 In press.

Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6.
Kaldate, RR, Haregewoin, A.
The Oncologist. 2012;17:296-302.

Body Surface Area-based Dosing of 5-Fluorouracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens.
Saam, J, Critchfield, GC, et al.
Clin Colorectal Cancer. 2011;10(3):203-206.

Multicenter Evaluation of a Novel Nanoparticle Immunoassay for 5-Fluorouracil on the Olympus AU400 Analyzer.
Beumer, J.H., Boisdron-Celle, M., et.al.
Therapeutic Drug Monitoring, 2009; 31(96), 688-94.

Pharmacokinetically guided dose adjustment of 5-Fluorouracil: A rational approach to improving therapeutic outcomes.
Saif, A., Choma, A, Salamone, S. & Chu, E.
Journal of the National Cancer Institute, 2009;101: 1 – 10.

5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A, Lencioni M, Amatori F, et al. Clin Cancer Res. 2008;14(9):2749-2755.

Will we ever be ready for blood level-guided therapy? [editorial].
Walko CM, McCloud HL.
J Clin Oncol. 2008;26(13):2078-2079.

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E, Delva R, Jacob J, et al.
J Clin Oncol. 2008;26(13):2099-2105.

ASCO Participants. 5-fluorouracil drug management pharmacokinetics and pharmacogenomics workshop; Orlando, Florida, January 2007 [meeting highlights].
Bertino J, Fleisher M, Beumer J, et al.
Clin Colorectal Cancer. 2007;6(6):407-422.

Paclitaxel

Personalized dosing of paclitaxel in patients with advanced non small-cell lung cancer: A simulation study.
Joerger, M., et al.
Clin Pharmacokinetics, 2012. in press.

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group.
Joerger, M, Alwin DR, et al.
Clin Cancer Res. 2007;13(221):6410-6418.

Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors.
Joerger, M., et al.
Clin Cancer Res, 2006;12(7 Pt 1):2150-2157.

Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer.
Mielke, S, Sparreboom, A., et al.
Clin Cancer Res. 2005;11(13):4843-4850.

Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller, A.A., et al.
Clin Cancer Res, 2004;10(24): 8325-8331.

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.
de Jonge, M.E., et al.
Clin Cancer Res, 2004;10(7): 2237-2244.

Nonlinear Pharmacokinetics and Metabolism of Paclitaxel and Its Pharmacokinetic/Pharmacodynamic Relationship in Humans.
Gianni, L, Kearns, CM, et al.
J Clin Onc. 1995;13(1):180-190.

Docetaxel

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study.
Engels, F. Loos, WJ, et al.
Clin Cancer Research. 2011;17:353-362.

Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice.
Minami, H., et al.
Cancer Sci. 2009;100(1):144-149.

Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly.
Ten Tije, AJ, Verweij, J, et al.
J Clin Oncol. 2005;23(6):1070-1077.

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
Rudek, MA, Sparreboom A, et al.
Eur J of Cancer. 2004;40:1170-1178.

Population Pharmacokinetics/Pharmacodynamics of Docetaxel in Phase II Studies in Patients with Cancer.
Bruno, R, Hille, D, et al.
J Clin Oncol. 1998;16(1):187-196.

Limited sampling models for the pharmacokinetics of docetaxel.
Lustig, V., H. Rosing, and Warmerdam, L.V. Clin Drug Invest. 1997;13(5):247-254.

Phase I and Pharmacokinetic Study of Taxotere (RP 56976; NSC 628503) Given as a Short Intravenous Infusion.
Extra, JM, Rousseau, F, et al.
Cancer Res. 1993;53:1037-1042.